Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Trial of Umbralisib and/or Ublituximab in B-cell Malignancies
NCT03207256Phase 2Terminated
- Sponsor
- TG Therapeutics, Inc.
- Start
- Aug 2017
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of umbralisib in chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), sponsored by TG Therapeutics, Inc.. Started Aug 2017; status: terminated.
02
Drugs
umbralisib
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03207256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207256.